Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Gastrointestinal safety and efficacy of long-term GCSB-5 use in patients with osteoarthritis: A 24-week, multicenter study

Authors
Ha, Chul-WonPark, Yong-BeomKyung, Hee-SooHan, Chung-SooBaeE, Ki-CheorLim, Hong-ChulPark, Sang-EunLee, Myung ChulWon, Ye-YeonLee, Dong-ChulCho, Sung-DoKim, Chang-WanKim, Jin-GooKang, Joon-SoonLee, Ju-HongChoi, Eui-SungSeon, Jong-KeunLee, Woo-SukBin, Seong-Il
Issue Date
2-8월-2016
Publisher
ELSEVIER IRELAND LTD
Keywords
GCSB-5; Shinbaro; Osteoarthritis; GI safety; Herbal medicine
Citation
JOURNAL OF ETHNOPHARMACOLOGY, v.189, pp.310 - 318
Indexed
SCIE
SCOPUS
Journal Title
JOURNAL OF ETHNOPHARMACOLOGY
Volume
189
Start Page
310
End Page
318
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/87836
DOI
10.1016/j.jep.2016.05.031
ISSN
0378-8741
Abstract
Ethnopharmacology relevance: A previous study indicated non-inferiority of GCSB-5 to celecoxib regarding efficacy and safety in treating OA; however, the gastrointestinal (GI) safety data was limited to 12 weeks. Accordingly, a longer term study with a larger number of patients was necessary to establish the GI safety of GCSB-5. Aim of study: The primary goal was to determine the safety and efficacy of 24-week use of GCSB-5. The secondary goal was to compare the GI safety data of GCSB-5 with that of the previously reported Celecoxib Long-term Arthritis Safety Study (CLASS). Method: This was a 24-week, multicenter, single-arm phase IV Study for the safety and efficacy of GCSB-5. A total of 761 patients were enrolled and 756 patients received at least one dose of GCSB-5. Among them, 629 patients (82.7%) completed the 24 week follow up. The primary goal was to determine the safety and efficacy of GCSB-5 for 24 weeks. The secondary goal was to compare the GI safety data of GCSB-5 with that of the previously reported Celecoxib Long-term Arthritis Safety Study (CLASS). Results: The incidence of GI disorders of GCSB-5 was 23.7%. The annual rate of perforation, ulcer obstruction, or bleeding (PUB) incidence was 0.0%. The drop-out rate due to GI disorders following GCSB-5 use was 4.8%. Compared to celecoxib data from CLASS, the incidence of GI disorders (23.7% vs. 31.4%, p < 0.001), annual rate of PUB and gastroduodenal ulcers (0.0% vs 2.2%, p = 0.004), and drop-out rate due to GI disorders following GCSB-5 use were significantly low (4.8% vs 8.7%, p < 0.001). Efficacy was proven by significant improvements in Western Ontario McMaster Questionnaire (WOMAC) scale, Korean Knee Score (KKS), 100-mm pain visual analogue scale (VAS), and physician's global assessments of patient's response to therapy (PGART). Conclusions: The safety and efficacy profile of GCSB-5 are comparable to celecoxib. These results indicate GCSB-5 is safe for a long-term treatment of knee OA patients. Trial registration: ClinicalTrials.gov (NCT01604239). (C) 2016 The Authors. Published by Elsevier Ireland Ltd. All rights reserved.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE